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Abstract
Hsp90 C-terminal inhibitors are advantageous for the development of new cancer
chemotherapeutics due to their ability to segregate client protein degradation from induction of the
prosurvival heat shock response, which is a major detriment associated with Hsp90 N-terminal
inhibitors under clinical investigation. Based upon prior SAR trends, a 1,2,3-triazole side chain
was placed in lieu of the aryl side chain and attached to both the coumarin and biphenyl scaffold.
Antiproliferative studies against SKBr3 and MCF-7 breast cancer cell lines demonstrated these
triazole-containing compounds to exhibit improved activity. These compounds were shown to
manifest Hsp90 inhibitory activity through Western blot analysis and represent a new scaffold
upon which more potent inhibitors can be pursued.
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Introduction
Developments in molecular biology have led to identification of new targets for the pursuit
of cancer chemotherapies during recent decades. The most successful demonstration thus far
is Gleevec, a small molecule BCR/ABL kinase inhibitor used for the treatment of chronic
myelogenous leukemia.1, 2 Due to their genetic instability and signaling redundancy, cancer
cells exhibit compensatory mechanisms and often acquire resistance to inhibition of a single
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protein.3 The most common approach to overcome this obstacle relies upon combination
therapy, in which inhibitors of multiple oncogenic targets are administered. In contrast, the
development of anti-cancer agents that target signaling nodes represent an alternative
method to target multiple signaling pathways simultaneously while minimizing the potential
for resistance.4, 5 The 90 kDa heat shock protein (Hsp90) represents a paradigmatic target
for the latter approach, as molecular chaperones are responsible for the conformational
maturation of signaling proteins associated with cancer cell growth and proliferation.6, 7 In
fact, recent studies indicated that almost 400 Hsp90-depedent client proteins have been
identified,8, 9 many of which are directly associated with the six hallmarks of cancer.10
Consequently, Hsp90 inhibition results in the simultaneous disruption of multiple signaling
pathways required for the viability of transformed cells. 17-AAG is a semi-synthetic
derivative of geldanamycin that targets the N-terminal ATP-binding site and exhibits
therapeutic benefit at tolerable doses in the clinic. In addition to 17-AAG, 16 other Hsp90
N-terminal inhibitors have been investigated in the clinical setting, which highlights the
importance of Hsp90 as a cancer therapeutic target.11 Unfortunately, these Hsp90 N-
terminal inhibitors induce the pro-survival heat shock response at the same concentration
needed to induce client protein degradation, resulting in primarily cytostatic activity. Thus,
the clinical effectiveness of Hsp90 N-terminal inhibitors remains unclear.12 In contrast to N-
terminal inhibitors, studies have demonstrated that inhibition of the Hsp90 C-terminus13 and
some allosteric modulators14,15 do not induce the heat shock response, and consequently
provides an attractive paradigm for the development of Hsp90 inhibitors that exhibit
improved activities.16,17
Seminal work by Neckers and coworkers reported that the DNA gyrase inhibitor,
novobiocin (1), and related natural products bind the Hsp90 C-terminus nucleotide binding
pocket with low affinity (IC50 ~700 μM).18 Subsequent modification to novobiocin
including alteration of coumarin scaffold, optimization of the benzamide side chain, and
replacement of the sugar moiety led to compounds that manifest increased inhibitory
activity.19–24 Although no co-crystal structure of Hsp90 bound to C-terminal inhibitors has
been solved, insights gained from SAR studies on novobiocin has produced valuable
information on the Hsp90 C-terminal binding pocket. Among the key elements on
novobiocin identified, the secondary amide linker and an aryl side chain were shown to be
particularly important9 (Figure 1A). Structural modification to these moieties has produced
analogues that exhibit improved activity, such as compound 2, which contains a simplified
coumarin core, a piperidine moiety, and a benzamide side chain (Figure 1B). Increasing
evidence suggests that hydrogen bonding interactions on the side chain are also beneficial,21
which is in accord with the improved activities observed for analogues possessing a 2-21 or
3-indole25 or a 4-methoxyphenyl23 side chain. Therefore, it was proposed that incorporation
of additional hydrogen bonding interactions could further increase inhibitory activity. In
addition, it was recently demonstrated that the coumarin core could be replaced with
simplified surrogates,26 which is imperative, due to the multi-step synthesis required for the
preparation of this ring system. Indeed, replacement of the coumarin ring (2) system with a
biphenyl scaffold (3) resulted in compounds that manifest increased antiproliferative activity
(Figure 1B).27 Therefore, it was proposed that incorporation of a hydrogen bonding ring
system onto both the coumarin and biphenyl scaffold could provide compounds that exhibit
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improved activity. Through exploratory methods, it was determined that the 1,2,3-triazole
moiety represents an optimal side chain surrogate for the benzamide side chain present in
novobiocin.
The copper catalyzed azido alkyne cycloaddition (CuAAC) reaction has found wide
application to various fields of chemistry, especially biomedical and medicinal chemistry,
due to the mild conditions required for assembly and its broad functional group
tolerance.28, 29 The product obtained from such reactions, the 1,2,3-triazole, is an amide
bioisostere that demonstrates enhanced hydrogen bonding interactions compared to the
amide. In addition, the triazole ring is present in various therapeutic classes due to its
hydrogen bonding capabilities and high dipole.29, 30 Prior studies have shown that
bioisosteric replacement of the amide linker on novobiocin with a 1,2,3-triazole resulted in
decreased antiproliferative activity,25 indicating that the amide N–H may be acting as a
hydrogen bond donor. Therefore, it was proposed to incorporate the 1,2,3-triazole into the
aryl side chain while retaining the secondary amide linker. To test this hypothesis,
compounds 4 and 5 were designed to combine the features noted above, wherein the noviose
sugar was replaced with a readily available piperidine moiety (Figure 1, C).22 The results
from these studies are presented herein and describe the identification of compounds that
manifest mid-nanomolar activity, which is ~1000 fold more efficacious than novobiocin.
Results and discussion
Retrosynthetically, coumarin derivative 4 was envisioned for assembly by an amide
coupling reaction between aniline 6 and triazolic acid 7, with the latter being accessed
through a CuAAC reaction between the corresponding azides and propiolic acid (Scheme 1).
Synthesis of both the phenyl and benzyl derivatives (4a and 4b) commenced by preparation
of 7a and 7b from propiolic acid and the corresponding azides.31 Aminocoumarin 6 was
prepared via reported procedures.22 Upon treatment with oxalyl chloride, triazolic acids 7a
and 7b were converted to the corresponding acid chlorides and coupled with aminocoumarin
6 to provide 4a and 4b (Scheme 2).
The cellular activity manifested by 4a and 4b was evaluated against a panel of cancer lines
(see supplemental material for details), including SKBr3 (estrogen receptor negative, Her2
over-expressing) lymphatic metastatic MDA-MB-468LN (estrogen receptor negative, Ah
receptor-positive) and MCF-7 (estrogen receptor positive) breast cancer cell lines, head and
neck squamous cell carcinoma (HNSCC) MDA1986 and JMAR cell lines, as well as
prostate cancer cell lines PC3-MM2 and LNCaP. Both compounds manifested activity at
low micromolar concentrations against all cell lines tested. Encouraged by these preliminary
studies, substitutions on the phenyl and benzyl side chains were explored to determine
structure-activity relationships for this series of compounds. Compounds 4c-q were
synthesized efficiently in a manner similar to 4a and 4b, from the substituted triazolic acids
7c-q and aniline 6 (Scheme 2). It was determined that both 4-chloro (4c) and 3-chloro (4f)
substitutions improved inhibitory activity against SKBr3 cell lines. Due to comparable
activities manifested by both the phenyl and benzyl analogues, studies were directed towards
modification of the benzyl ring system. Electron-donating groups such as 4-methyl (4i) and
4-methoxy (4j) as well as 4-chloro analogues (4g) manifested similar potencies compared to
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the unsubstituted analogue, 4b. However, the 4-NO2 substituent (4l) exhibited improved
activity against all cancer cell lines tested, manifesting an IC50 of 0.38 and 0.64 μM against
SKBr3 and MCF-7 cell lines, respectively. Sterically bulky groups such as 4-tert-butyl (4k)
were found favorable, although their effects on the MCF-7 cell line were not clear. When a
hydrophobic cyclohexylmethyl group was installed as the appendage (4q), improved
inhibitory activities against SKBr3, MDA1986 and JMAR cells were observed, indicating
the existence of a hydrophobic region in this area of the binding pocket. Although current
data is limited and warrants further investigation, the observed inhibitory activities
manifested by these triazole-containing analogues indicate that hydrogen bonding
interactions on the side chain are favorable for Hsp90 C-terminal inhibition, which might
result from either direct hydrogen bonding interactions or conformational rigidity on the side
chain which might direct hydrophobic substituent into the hydrophobic pocket.
Increasing flexibility between the triazole side chain and the terminal phenyl ring was
sought to determine whether improved inhibitory activity could be achieved. Therefore,
compounds bearing two (4r) or three carbons (4s) were synthesized by an amide coupling
reaction between the corresponding triazolylic acids (7r and 7s) and amine 6 (Scheme 2).
The antiproliferative activities manifested by these compounds were then determined. A
comparison of the data shown for 4a-b and 4r-s (Table 1) illustrates that compound 4r,
which contains a two carbon linker, exhibited the most improved activity amongst the four
analogues evaluated, exhibiting IC50s of 130 nM against SKBr3 cell line and about 110 nM
against MDA1986 cell line.
To confirm that the observed antiproliferative activities were resulting from Hsp90
inhibition, western blot analyses of Hsp90 client proteins in MCF-7 cell lysates were
performed. Actin, whose maturation does not require the Hsp90 machinery, was used as a
control. As shown in Figure 2, Hsp90 client proteins Her2, Akt and Raf-1 were degraded
upon exposure of 4f, 4o or 4q at concentrations that mirror their anti-proliferative values,
confirming that cell viability is directly linked to Hsp90 inhibition.
Attention was then shifted to determine whether the anti-proliferative activities of these
derivatives were similar to those of the recently identified biphenyl ring system. Biphenyl
aniline 8 was synthesized according to a previously reported procedure.25 Similar to the
coumarin derivatives, triazolylic acids 7a-b, 7g-q, 7r and 7t were converted to their acid
chlorides upon treatment with oxalyl chloride, followed by coupling with aniline 8 to
generate the biphenyl containing derivatives 5a-o (Scheme 3).
The antiproliferation activities manifested by these compounds are reported in Table 2. In
contrast to the coumarin-based analogues 4a and 4b, which showed similar anti-proliferative
activity, the phenyl and benzyl analogues 5a and 5b displayed very different activities, with
the latter being about 2.5~8 times more potent against all the cell lines evaluated,
manifesting IC50s of 170 and 500 nM against SKBr3 and MCF-7 cell lines, respectively. A
compound that contains the two carbon linker (5c) was found to exhibit activity similar to
those of the benzyl analogue, 5b. Subsequent studies were then aimed to modify the
benzylic ring. As can be seen in Table 2, halogens at the 4-position were in general
detrimental to inhibitory activity (5d-e); while electron-donating groups such as 4-methyl
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(5f) and 4-methoxy (5g) retained potencies against SKBr3 and MDA-MB-468LN cells, but
manifested increased inhibitory activities against the MCF-7 cell line (120 and 270 nM,
respectively) and prostate cancer cell lines. 3-Chloro (5k), 3-methoxy (5l), and 2-chloro
(5m) produced decreased activity against SKBr3 cells, but increased activities against
MCF-7 and MDA-MB-468LN cells. Combination of 2-chloro and 4-methyl substitution
(5n) retained activity against SKBr3 cells, but did not improve activity against MCF-7 cells
compared to the 4-methyl substituted analogue, 5f. However, this combination indeed
improved activities against MDA-MB-468LN, MDA1986 and LNCaP cell lines. Of
particular note, the 4-tert-butyl substituted analogue, 5h, manifested decreased
antiproliferative activity against all cell lines tested compared to the 4-methyl analogue, 5f,
which is in contrast to the coumarin derivatives 4i and 4k, indicating a smaller hydrophobic
pocket exists when the biaryl scaffold is present. Similar to the coumarin scaffold,
replacement of the benzyl group with a cyclohexylmethyl substituent resulted in compounds
that manifested good inhibitory activities. Differences in the structure-activity relationships
for the two scaffolds suggest the biphenyl ring system presents the side chain through
different binding interactions. In general, installation of triazole side chain on the recently
identified biphenyl side chain greatly improves antiproliferative activitiy against a wide
spectrum of cell lines, resulting in more potent analogues.
The cellular activity manifested by these biphenyl analogues was shown to result from
Hsp90 inhibition by performing western blot analyses of MCF-7 cell lysates treated with
such compounds. Hsp90-dependent client proteins were decreased upon exposure to of 5b,
5f and 5g at concentrations that mirror their antiproliferative IC50s. Clear degradation of
Hsp90 client proteins Her2, Akt and Raf-1 was observed, while actin, which does not rely
upon the Hsp90 chaperone machinery, remained constant, indicating that the
antiproliferative activities manifested by these compounds resulted from Hsp90 inhibition
(Figure 3A). These client proteins Her2, Akt, Raf-1 and CDK6 were also degraded in a
concentration-dependent manner upon exposure to the most potent analogue 5f and the
representative analogue 5b, against MCF-7 cells (Figure 3B and 3C), while actin levels
remain unchanged. Examination of hsp90 expression when exposed to these compounds
have shown that while GDA, the positive control, induced hsp90 upregulation due to
induced heat shock response, hsp90 levels were constant or even decreased upon treatment
of these compounds (Fig. 3), consistent with the observations manifested by many Hsp90 C-
terminal inhibitors,20, 22, 24, 27, 32 indicating that these compounds exhibit hsp90 inhibitory
activity through C-terminal inhibition. It is worthwhile to note that at a concentration as low
as 1 μM, 5f was able to deplete hsp90 client proteins as well as Geldanamycin at 500 nM,
demonstrating the remarkable activity exhibited by this compound for Hsp90 inhibition.
Furthermore, no increase in heat shock proteins Hsp27, Hsp70, or Hsp90 was observed with
increasing concentrations of 5f (Figure 4A). Depletion of client proteins without increased
levels of heat shock proteins is a hallmark of Hsp90 C-terminal inhibition. To determine
whether 5f binds the Hsp90 C-terminus, proteolytic fingerprinting of Hsp90 from TnT rabbit
reticulocyte in the presence of 5f was performed. Novobiocin locks Hsp90 in the “open
conformation” when bound to the C-terminus33, 34. In this conformation, amino acids
Lys615 and Arg620 are not solvent exposed and are “protected” from cleavage by trypsin.
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This results in bands that differ in molecular weight from vehicle control. The C-terminal
Hsp90 antibody AC88 detects the emergence of a 50 kDa band in the presence of
novobiocin and other C-terminal inhibitors. A 50 kDa band was detected with 5 mM
novobiocin and 1 mM 5f that is not detected for the vehicle control (Figure 4B). Together,
these data further support that 5f binds and inhibits the Hsp90 C-terminus, which leads to
client protein degradation without induction of the heat shock response.
A brief summary of observed structure-activity relationships for these derivatives is depicted
in Figure 5. In support of the existence a hydrophobic pocket, incorporation of either an
aromatic or saturated carbocycle was found favorable to inhibitory activity. Two carbons
were found optimal for the coumarin derivatives, compared to one carbon for the biphenyl
derivatives; and suggests that projection of the side chain is different for the biaryl scaffold.
This observation is further supported by the tolerance of bulky groups exhibited at the para
position of benzylic moiety (4k), but not for the biphenyl derivative, 5h. These observations
highlight the significance of both hydrogen bonding and hydrophobic interactions at this
location of the Hsp90 C-terminal binding pocket.
Conclusion
In conclusion, a series of 1,2,3-triazole side chain containing analogues that contain the
coumarin or biphenyl backbone were designed, synthesized and evaluated for
antiproliferative activities against a panel of breast, HNSCC, and prostate cancer cell lines.
Compounds manifesting nanomolar activity were identified through preliminary SAR
studies and their Hsp90 inhibitory activity confirmed by Western blot analysis. The
improved Hsp90 inhibitory activities exhibited by these compounds might result from
increased hydrogen bonding properties on the amide side chain when connected to a
hydrophobic appendage, or from the conformational rigidity due to the incorporation of
1,2,3-triazole which directs the hydrophobic appendage into the hydrophobic pocket. These
observations are expected to aid in the development of more potent Hsp90 C-terminal
inhibitors, and such studies will be reported in due course.
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Refer to Web version on PubMed Central for supplementary material.
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The design of novel hsp90 C-terminal inhibitors.
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Western blot analyses of the Hsp90 client protein degradation in MCF-7 breast cancer cells
lysis after treatment of triazole analogues. L represents a concentration 1/2 of the anti-
proliferative IC50 value, while H represents a concentration 5 times the antiproliferative IC50
value. Geldanamycin (G, 500 nM) represents a positive control, while DMSO (D), vehicle,
serves as the negative control.
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Western blot analyses of the Hsp90 client protein degradation in MCF-7 breast cancer cells
lysis 24 h after treatment of biphenyl triazole analogues 5b, 5f and 5g. (A) L represents a
concentration 1/2 of the anti-proliferative IC50 value, while H represents a concentration 5
times the antiproliferative IC50 value. (B) Concentrations (in μM) of 5f are indicated above
each lane. (C) Concentrations of 5b (in μM) are indicated above each lane. Geldanamycin
(G, 500 nM) and DMSO (D) were employed respectively as positive and negative controls.
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(A) Western blot analyses of the heat shock proteins Hsp27, Hsp70 and Hsp90 in MCF-7
breast cancer cells lysis 24 h after treatment with 5f. Concentrations (in μM) of 5f are
indicated above each lane. Geldanamycin (G, 500 nM) and DMSO (D) are positive and
negative controls. (B) Proteolysis of Hsp90 from TnT reticulocyte lysate incubated under
conditions of protein synthesis with vehicle (1% DMSO) 5mM novobiocin and 1mM 5f. An
antibody specific to the C-terminus of Hsp90 was used to identify the Hsp90 fragments
produced in the presence of increasing amounts of trypsin.
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A summary of SARs for triazole containing coumarin and biphenyl derivatives.
Zhao et al. Page 12























Retrosynthetic analysis of the triazole 4.
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Synthesis of triazole containing coumarin derivatives.
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Synthesis of biphenyl triazole derivatives 5.
Zhao et al. Page 15


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medchemcomm. Author manuscript; available in PMC 2015 September 01.
